A randomized phase 2 study of paclitaxel and carboplatin with or without conatumumab for first-line treatment of advanced non-small-cell lung cancer. - Wikidata - awgldk - TriplyDB

A randomized phase 2 study of paclitaxel and carboplatin with or without conatumumab for first-line treatment of advanced non-small-cell lung cancer.

A randomized phase 2 study of paclitaxel and carboplatin with or without conatumumab for first-line treatment of advanced non-small-cell lung cancer.

http://www.wikidata.org/entity/Q33405622

about

Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy Targeting the apoptosis pathway in hematologic malignancies Getting TRAIL back on track for cancer therapy Caspase-8 expression is predictive of tumour response to death receptor 5 agonist antibody in Ewing's sarcoma TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells.Results on efficacy and safety of cancer treatment with or without tumor necrosis factor-related apoptosis-inducing ligand-related agents: A meta-analysis.Lung cancer: Biology and treatment options.Triptolide enhances the tumoricidal activity of TRAIL against renal cell carcinoma Prognostic factors for long term survival in patients with advanced non-small cell lung cancer.Phase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer.Targeting TNF-related apoptosis-inducing ligand (TRAIL) receptor by natural products as a potential therapeutic approach for cancer therapy Therapeutic applications of TRAIL receptor agonists in cancer and beyond.Monoclonal antibodies for the treatment of non-haematological tumours: update of an expanding scenario.Safety and tolerability of TRAIL receptor agonists in cancer treatment.Targeting TRAIL in the treatment of cancer: new developments.Journey of TRAIL from Bench to Bedside and its Potential Role in Immuno-Oncology.Combination of systemic chemotherapy with local stem cell delivered S-TRAIL in resected brain tumors.Selective Targeting of Myeloid-Derived Suppressor Cells in Cancer Patients Using DS-8273a, an Agonistic TRAIL-R2 Antibody.FOLFIRI plus dulanermin (rhApo2L/TRAIL) in a patient with BRAF-mutant metastatic colon cancer.TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic colorectal cancer: A randomized phase 1b/2 trial.Death Receptors: New Opportunities in Cancer Therapy.Loss of functional BAP1 augments sensitivity to TRAIL in cancer cells.Nanoparticles for Immune Cytokine TRAIL-Based Cancer Therapy.Structural principles of tumor necrosis factor superfamily signaling.Developing TRAIL/TRAIL death receptor-based cancer therapies.Dasatinib promotes TRAIL-mediated apoptosis by upregulating CHOP-dependent death receptor 5 in gastric cancer.

P2860

Q26993238-A11D4286-A587-4223-8D82-0C9C49678B6E Q27024422-0683DDEF-E6BA-4E1A-99C2-2717B037C076 Q27027460-8BB4AD9C-8594-4D62-AC04-AD5CA81154A0 Q27853200-FDBB2A5B-7E65-4B0E-A110-8DC8DB5E0F2B Q34557885-B823B38D-3B1A-4AE7-96AE-10B63652E81D Q35158520-F19E32DC-E639-4E75-A3AA-C3E4B996A3C2 Q36328370-5F019CD1-B9A7-4CD9-824C-530971CD1DC6 Q36470781-C1ACCD64-98B8-49DA-89ED-F73E7269C2A1 Q36924926-622B8F1E-EDB1-41D5-9B8B-84BCA521E0DB Q36938811-37BB60B9-283A-443F-A4E8-3223C90C03DD Q37071019-F1FC2321-1CA8-4209-AAF5-CFB2100B9A45 Q37114025-696201D6-0D51-448C-9297-742ADDE5BB4E Q38253815-78E85963-1C74-4B77-9703-1A8D3A410045 Q38363946-04A9EAC7-6528-4EED-8571-38A5A5456DF1 Q38500801-98D1738E-5263-440E-89B5-C879D208A979 Q38557486-7BC656BD-2CE9-4248-97C0-D081A6BD0B2D Q38960128-05A37453-2839-4CAB-A7E3-8D91F39C7A0B Q39103948-4FFCDC13-C290-429E-8D06-69F0CA3A87A0 Q42203684-B7F81A0E-6F14-4C28-B9A4-0831337D1E8C Q42623198-7958C5ED-06C0-4215-B644-43906F3D21FC Q47108799-055C91D7-8C9B-46D0-B033-32176CFA94EA Q47653923-9B564A9B-F426-4202-8925-D607FA10DC45 Q47707153-5CD81B8E-85F1-4C6E-9BE5-546F890071EE Q48319204-F6FA50B1-5FD9-403B-A118-8292E0D56D99 Q53701901-0328F21C-3E3B-43AC-A6D8-318C25CABF17 Q54111073-59D2EB24-3D8C-4BE1-B861-12BD78360958

P2860

A randomized phase 2 study of paclitaxel and carboplatin with or without conatumumab for first-line treatment of advanced non-small-cell lung cancer.

http://www.wikidata.org/entity/Q33405622

description

2013 nî lūn-bûn

@nan

2013 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի մարտին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

A randomized phase 2 study of ...... ed non-small-cell lung cancer.

@ast

A randomized phase 2 study of ...... ed non-small-cell lung cancer.

@en

type

label

A randomized phase 2 study of ...... ed non-small-cell lung cancer.

@ast

A randomized phase 2 study of ...... ed non-small-cell lung cancer.

@en

prefLabel

A randomized phase 2 study of ...... ed non-small-cell lung cancer.

@ast

A randomized phase 2 study of ...... ed non-small-cell lung cancer.

@en

P1433

Q33405622-8ACEF555-BBCD-47CF-97AF-7328B21B9BC8

P1476

Q33405622-D233CF34-BF56-4ABF-B956-6533377928BD

P2093

Q33405622-228278A1-0FAF-4A0E-BB18-812CDA3E354E

Q33405622-27D605F4-7BA1-403C-B26B-733EA5F42816

Q33405622-29E03B81-685E-4500-A3DC-22009D2B2FAC

Q33405622-3EDB7F0B-45D3-4BC5-97FB-77F73BD6845A

Q33405622-8F2145BE-E7FC-49CD-8B82-11254F44E57D

Q33405622-970CB1A3-AD74-4142-B0C9-1DCD27B4816D

Q33405622-97E16743-AC4C-4B2B-8971-25A24E975DF3

Q33405622-A157C23F-CA9A-4650-93BA-3A156BD8D82B

Q33405622-ABA8BCBA-1730-461B-B8BE-C42F80D46AD1

Q33405622-C9CC932C-4BE8-4532-9273-855ABDE44A28

P304

Q33405622-508800B8-9C37-4F00-9E05-7F1670E1B70D

P31

Q33405622-C1FBB85E-E8BF-422E-8BCA-E0A4F5004E4A

P356

Q33405622-4FF63489-C85B-447D-8F28-22B4AEA12B33

P433

Q33405622-C8FDEEF9-E5CE-49DD-9508-D9B097574856

P478

Q33405622-5145E6DA-E38D-4998-8127-9E2F6A6A439A

P50

Q33405622-CC593539-236C-493A-BA86-219FE9BE919A

P577

Q33405622-B6E33FBF-5A10-4170-96B1-6D11C3FC087D

P698

Q33405622-E244CE00-4461-4FAC-8918-5F2F8E32918C

P356

JTO.0B013E31827CE554

P1433

Journal of Thoracic Oncology

P1476

A randomized phase 2 study of ...... ed non-small-cell lung cancer.

@en

P2093

Beatrix Bálint

http://www.w3.org/2001/XMLSchema#string

Cheng-Pang Hsu

http://www.w3.org/2001/XMLSchema#string

Francesco Galimi

http://www.w3.org/2001/XMLSchema#string

Jan P van Meerbeeck

http://www.w3.org/2001/XMLSchema#string

Luis Paz-Ares

http://www.w3.org/2001/XMLSchema#string

Paul De Souza

http://www.w3.org/2001/XMLSchema#string

Rafal Wierzbicki

http://www.w3.org/2001/XMLSchema#string

Richard H de Boer

http://www.w3.org/2001/XMLSchema#string

Susan Cottrell

http://www.w3.org/2001/XMLSchema#string

Tony Sabin

http://www.w3.org/2001/XMLSchema#string

P304

329-337

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/JTO.0B013E31827CE554

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23370314

http://www.w3.org/2001/XMLSchema#string